Dr. Emerson A. Lim, MD

Dr. Lim practices at Corewell Health Grand Rapids Hospitals - Butterworth in Grand Rapids, Michigan, part of Corewell Health.

Dr. Lim's NPI, 1407030307, was assigned on December 27, 2007. Dr. Lim graduated from New York University School of Medicine in 2006. Dr. Lim holds New York license 246724.

Dr. Lim's primary practice is Corewell Health Grand Rapids Hospitals - Butterworth, at 100 Michigan St NE, Grand Rapids, MI 49503 in Kent County. The practice phone is (616) 391-1774.

Dr. Lim's primary practice is Corewell Health Grand Rapids Hospitals - Butterworth in Grand Rapids, Michigan, part of Corewell Health. Dr. Lim is also affiliated with Corewell Health Zeeland Hospital. The medical group on file is Corewell Health Medical Group West. Dmand AI also links Dr. Lim to 3 more hospitals, 9 medical groups and 5 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lim practices, 10 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Lim's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Lim is licensed in New York.

CMS data shows 431 Medicare services from Dr. Lim across 6 procedure codes in 2024, for 159 Medicare patients. Medicare paid $32,084 for them.

CMS counts 159 Medicare patients who saw Dr. Lim in 2024. The largest group is 65 to 74, with 69 patients. 75% of them have cancer, and 75% have high blood pressure. 20% are also on Medicaid. Their average risk score is 2.25, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lim's median patient age at 70, with 33% women.

In 2024, Dr. Lim wrote 1,944 Medicare Part D claims for 252 patients. 88% of them were for generic drugs. CMS names the drug for 1,750 of them, across 25 drugs with 11 or more claims each, at $4,207,588 in total drug cost. In 2023, CMS named 1,127 claims across 20 drugs.

Dr. Lim accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 23 papers to Dr. Lim, published from 2013 to 2024. 2013 was the busiest year, with 3. The most frequent topics are Antineoplastic Agents, Prostatic Neoplasms, Castration-Resistant and Antineoplastic Combined Chemotherapy Protocols. Dr. Lim has published most often in Cancer Invest. Dr. Lim's most frequent co-authors are Dawn Lauryn Hershman, MD, Alfred I. Neugut, MD, PhD and Katherine D. Crew, MD, MS.

Dmand AI links Dr. Lim to 8 clinical trials, 4 of them phase 1/2 studies. 5 are still active or recruiting. Conditions studied include Prostatic Neoplasms, Prostatic Diseases and Carcinoma, Merkel Cell. Columbia University sponsors the most, 2.

CMS Open Payments shows 8 general payments to Dr. Lim from 5 drug and device companies from 2016 to 2024. Food and beverage make up the largest share, 94% of the total. AstraZeneca Pharmaceuticals LP paid the most, $121.

Dr. Lim graduated from New York University School of Medicine in 2006.